Mayan Katz

MAYAN KATZ advises publicly held and private companies, investors, and founders on a wide range of strategic transactions and corporate matters. His practice focuses on the life sciences, biotechnology, medical device, pharmaceutical, and digital healthcare sectors. He counsels clients across the corporate lifecycle, from formation through exit, including emerging company, venture and growth financings, mergers and acquisitions, and complex transactions.

Mayan has significant experience representing buyers and sellers in domestic and cross-border mergers and acquisitions, including structured transactions, divestitures, spin-outs, joint ventures, option and build-to-buy deals, and royalty monetization. Drawing on deep experience in the life sciences sector, Mayan regularly counsels both companies and investors on early, late-stage, and growth financings, corporate governance matters, and strategic transactions. His practice emphasizes practical, business-oriented advice tailored to companies operating in highly innovative and regulated industries.

Mergers and Acquisitions and Strategic Transactions

• A subsidiary of Piramal Pharma on its acquisition of the global rights to Kenalog® from Bristol-Myers Squibb.
• instiro in its acquisition of CombinAble.AI.
• Q32 Bio on the sale of its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics.
• Ophthalmic medical device company LumiThera on its acquisition by Alcon.
• PKG Health in its acquisition by Empatica.
• Kronons Bio in the sale of its clinical pipeline to Ignota Labs.
• Biotheus on its acquisition by BioNTech.
• Anika Therapeutics on the divestiture of its Arthrosurface business.
• A subsidiary of Dr. Reddy’s Laboratories in its acquisition of the U.S. generic prescription product portfolio of Mayne Pharma.
• Teva Pharmaceutical Industries and its subsidiaries in connection with multiple divestitures, including US store-brand over-the-counter (OTC) and nicotine replacement therapy (NRT) businesses.
• Johnson & Johnson and its subsidiaries in connection with:
  • The sale of one of its drug product lines to Baxter International.
  • The strategic alliance with Apple to deploy the Apple Watch to detect atrial fibrillation and the launch of the Heartline™ Study.
  • The transfer of collaboration rights and assets to Pharma Mar.
  • The US$155 million sale of injectable anesthesia and pain management products to Piramal Enterprises’ critical care division.
  • The spin-out of Tusker Medical Inc. to Apple Tree Partners.
• Innoviva in its acquisition of the LYNX platform from Lyndra Therapeutics.
• Aurobac Therapeutics SAS in its acquisition of substantially all intellectual property assets of ContractFect Corporation in a Chapter 7 transaction.
• Ji Xing Pharmaceuticals Limited in its acquisition of global rights to PB6440 from PhaseBio Pharmaceuticals.
• Pharma Two B in its subsequently terminated merger agreement with Hepion Pharmaceuticals.
• Biosight in its merger with Ayala Pharmaceuticals.
• bluebird bio in its strategic alliance with National Resilience and the related acquisition by Resilience of bluebird’s manufacturing facility in North Carolina for US$110 million.
• Centessa Pharmaceuticals in its US$250 million financing round in parallel with the simultaneous acquisition by Centessa of 10 private biotech companies across four jurisdictions.
• Cadent Therapeutics in its acquisition by Novartis for up to US$770 million, including an upfront payment of US$210 million and up to US$560 million in milestone payments.
• AMAG Pharmaceuticals in connection with:
  • The divestment of its women’s health assets.
  • The sale of its rights to Intrarosa® to Millicent Pharma for up to US$125 million.
• Zealand Pharma in its US$205 million royalty and milestone monetization from Royalty Pharma.

Venture Capital, Private, and Public Financings

• Third Rock Ventures in connection with the US$165 million Series A financing launch of Syremis Therapeutics.
• PreDICTA Biosciences in its US$23.4 million Series A financing and earlier financings.
• Atrandi Biosciences in its US$25 million Series A financing.
• Brandon Capital Partners in its investments in Azura Ophthalmics.
• Cobro Ventures in its investments in TechsoMed.
• Harbour BioMed and Kelun-Biotech in the US$200 million Series A financing launch of Windward Bio.
• The investor syndicate in the €80 Million Series A Financing of Antag Therapeutics.
• ZymoChem in its US$21 million Series A financing.
• Nested Therapeutics its US$125 million financing launch.
• Cathay Health, Polaris Partners, and Newpath Partner in their investments as lead investors in the US$60 million Series A financing of Kojin Therapeutics.
• Johnson & Johnson and its subsidiaries in connection with the investment as lead investor of the US$1.3 billion Series B financing of Grail, Inc., which was named LMG Life Sciences 2017 “Impact Deal of the Year.”
• EQRx in connection with:
  • Its US$1.8 billion business combination with CM Life Sciences III.
  • Its US$500 million Series B financing.
  • Its US$200 million Series A financing.
• Clarus Therapeutics in connection with:
  • Its business combination with Blue Water Acquisition Corp.
  • Its senior debt financing of up US$75 million.
  • Its convertible note financings.
• Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp. II.
• Stablix Therapeutics in its US$63 million Series A financing.
• Orbia Ventures in connection with multiple investments, including:
  
  • Its investment as lead investor in the US$21 million Series B financing of Battery Resources.
  • Its investment in Silvec Biologics.
  • Its US$3 investment in SeeTree.
• Augmedics in its US$36 million Series C financing.
• 5AM Ventures in its investment as lead investor in the US$78 million Series A financing and US$120 million Series B financing of Artiva Biotherapeutics.
• Perceptive Advisors in its investment as lead investor in the US$85 million Series B financing of Athira Pharma.

The above matters were handled prior to joining Sidley.

Mayan has counseled on multiple pro bono legal clinics, and regularly advises non-profit organizations in connection with corporate governance and transactional matters.